SAM
GILD icon

Symphony Asset Management’s Gilead Sciences GILD Stock Holding History

Symphony Asset Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-100,000
Closed -$5.13M – 368
2013
Q2 		$5.13M Buy
+100,000
New +$5.21M 0.49% 54

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Symphony Asset Management's GILD Position: Q3 2018 in Review

Symphony Asset Management sold out of Gilead Sciences (GILD) in Q3 2018, closing a stake of 22,771 shares — an estimated $1.72M sold.

Symphony Asset Management first reported a position in GILD in Q2 2013 and held it in 21 quarters. The position peaked at $6.09M in Q1 2016. 1,527 funds tracked by Wall St. Rank hold GILD as of Q3 2018.

  • Symphony Asset Management reported no remaining Gilead Sciences position as of Q3 2018 after selling out during the quarter.
  • Symphony Asset Management sold 22,771 Gilead Sciences shares in Q3 2018, an estimated $1.72M.
  • Symphony Asset Management first reported a position in Gilead Sciences in Q2 2013 and held it in 21 quarters.
  • Symphony Asset Management's Gilead Sciences position peaked at $6.09M in Q1 2016.
  • 1,527 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2018.

Based on Symphony Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.